Inclusion Body Myositis Clinical Trial
Official title:
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis Detailed Description: A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis Detailed Description: This is a Phase II/III randomized, double-blind, placebo-controlled, parallel multicenter study with 3 parts. The study will include a sentinel cohort (Part A) of 30 subjects who will receive first three doses of the study drug. Safety data from subjects in the sentinel cohorts will be evaluated by a Data and Safety Monitoring Board (DSMB) before further dosing of the sentinel cohort, as well as initiation of enrollment in the double-blind safety and efficacy cohort (Part B). After completion of Part A or Part B, subjects have the option of enrolling in an open-label long-term extension study or progressing to the pharmacodynamics (PD) recovery cohort (Part C), to evaluate the recovery of the depletion of killer cell lectin-like receptor G1 (KLRG1)+ cells after the end of treatment with ABC008. Efficacy, safety, HRQoL, and HRU assessments will be conducted. Blood samples will be obtained to evaluate the serum PK, PD, and immunogenicity of ABC008 throughout the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00769860 -
Arimoclomol in Sporadic Inclusion Body Myositis
|
Phase 2/Phase 3 | |
| Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
| Active, not recruiting |
NCT05046821 -
Sporadic Inclusion Body Myositis Natural History Study
|
||
| Recruiting |
NCT06153108 -
Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
|
||
| Active, not recruiting |
NCT04659031 -
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
|
Phase 1 | |
| Completed |
NCT03440034 -
Study of Pioglitazone in Sporadic Inclusion Body Myositis
|
Phase 1 | |
| Terminated |
NCT04049097 -
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
|
Phase 3 | |
| Completed |
NCT00001261 -
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
|
Phase 2 | |
| Recruiting |
NCT05272969 -
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
|
||
| Completed |
NCT01734369 -
Environmental Risk Factors for Myositis in Military Personnel
|
||
| Active, not recruiting |
NCT04975841 -
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
|
N/A | |
| Recruiting |
NCT00017914 -
Adult and Juvenile Myositis
|
||
| Completed |
NCT00917956 -
Lithium in Inclusion Body Myositis (IBM)
|
N/A | |
| Completed |
NCT03633318 -
Establishing Muscle Impedance Parameters With Electrical Impedance Myography
|
||
| Recruiting |
NCT04789070 -
Phase III Trial of Sirolimus in IBM
|
Phase 3 | |
| Recruiting |
NCT05032131 -
Cell Therapy for IBM by Muscle Injection of ADSVF
|
Phase 1 | |
| Completed |
NCT03299335 -
Molecular Profile of the Evolution of Inclusion Body Myositis
|
N/A | |
| Completed |
NCT04421677 -
Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
|
Phase 1 | |
| Completed |
NCT02753530 -
Study of Arimoclomol in Inclusion Body Myositis (IBM)
|
Phase 2 |